Corbus Pharmaceuticals Holdings, Inc. (CRBP) · Oct 15, 2026 · Other events

Corbus clinical update backs obesity drug, advances CRB-701

Pipeline update — CRB-913 5% weight loss; CRB-701 43% OPSCC ORR

Corbus’ clinical update fills in CRB-913 obesity and CRB-701 cancer data, but mostly confirms milestones already known to investors.

Corbus is a clinical-stage biotech advancing two main assets: CRB-701 toward a registrational throat-cancer study and CRB-913 toward Phase 2 obesity development. The broad setup was already public through the company’s second-quarter update and the September 14, 2026 CANYON-1 topline release, so this presentation is mainly a fuller investor narrative rather than a fresh catalyst.

CRB-701 remains the more advanced business opportunity. The presentation highlights 42.9% confirmed response in second-line OPSCC at the 3.6 mg/kg dose, with median progression-free survival of 5.6 months, and 34.4% response in cervical cancer at the same dose. Those figures support the company’s decision to move into TEMPO-1, but they remain small, non-randomized Phase 1/2 data rather than registration-grade evidence. 〔0〕

Program / settingKey figureWhat it means
CRB-701, OPSCC, 3.6 mg/kg42.9% cORR; 5.6-month PFSSupports the registrational dose
CRB-701, cervical cancer, 3.6 mg/kg34.4% cORR; 4.3-month PFSPotential differentiation versus existing second-line treatment
CRB-913, 60 mg5.0% placebo-adjusted weight loss at 12 weeksEstablishes a clinical signal for Phase 2
Cash, cash equivalents and investmentsApproximately $118 million at June 30, 2026Provides funding visibility, though not a complete development budget

CRB-913 clears the first hurdle, but not the commercial one. The 5% placebo-adjusted weight loss at 12 weeks, with no apparent plateau, gives Corbus a reason to advance its non-incretin oral obesity program. The safety framing is encouraging in the short study, but the comparison with GLP-1 drugs is cross-trial and the program still needs longer-duration data showing whether weight loss persists and tolerability holds.

The presentation mostly confirms an already-known milestone path. TEMPO-1 had already been expected to start in September 2026, CRB-701 plus pembrolizumab data are targeted for the first quarter of 2027, and the CRB-913 Phase 2 monotherapy study is expected in the first half of 2027. 〔1〕 〔2〕

Bottom line: This is a substantive pipeline refresh, but not a major expectation reset. It strengthens the case that both programs are progressing, while leaving the next meaningful proof points—registrational CRB-701 data and longer-term CRB-913 efficacy and safety—still ahead.

What to watch next

ObesityWeek presentation, November 14–17, 2026

Original filing on SEC EDGAR

Corbus clinical update backs obesity drug, advances CRB-701 | CRBP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.